Suppr超能文献

积极降低低密度脂蛋白胆固醇水平及小剂量抗凝对大隐静脉冠状动脉旁路移植血管阻塞性病变的影响。

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.

机构信息

Post CABG Coordinating Center, Maryland Medical Research Institute, Baltimore 21210, USA.

出版信息

N Engl J Med. 1997 Jan 16;336(3):153-62. doi: 10.1056/NEJM199701163360301.

Abstract

BACKGROUND

Obstructive changes often occur in aortocoronary saphenous-vein bypass grafts because of atherosclerosis and thrombosis. We studied whether aggressive lowering of low-density lipoprotein (LDL) cholesterol levels or low-dose anticoagulation would delay the progression of atherosclerosis in grafts.

METHODS

We studied 1351 patients who had undergone bypass surgery 1 to 11 years before base line and who had an LDL cholesterol level between 130 and 175 mg per deciliter and at least one patent vein graft as seen on angiography. We used a two-by-two factorial design to assign patients to aggressive or moderate treatment to lower LDL cholesterol levels (with lovastatin and, if needed, cholestyramine) and to treatment with warfarin or placebo. Angiography was repeated an average of 4.3 years after base line. The primary angiographic outcome was the mean percentage per patient of grafts with a decrease of 0.6 mm or more in lumen diameter.

RESULTS

As measured annually during the study period, the mean LDL cholesterol level of patients aggressive treatment ranged from 93 to 97 mg per deciliter; with moderate treatment, the range was from 132 to 136 mg per deciliter (P<0.001). The mean international normalized ratio was 1.4 in the warfarin group and 1.1 in the placebo group (P<0.001). The mean percentage of grafts with progression of atherosclerosis was 27 percent for patients whose LDL cholesterol level was lowered with aggressive treatment, and 39 percent for those who received moderate treatment (P<0.001). There was no significant difference in angiographic outcome between the warfarin and placebo groups. The rate of revascularization over four years was 29 percent lower in the group whose LDL cholesterol level was lowered aggressively than in the group receiving moderate treatment (6.5 percent vs. 9.2 percent, P= 0.03).

CONCLUSIONS

Aggressive lowering of LDL cholesterol levels to below 100 mg per deciliter reduced the progression of atherosclerosis in grafts. Low-dose warfarin did not reduce the progression of atherosclerosis.

摘要

背景

由于动脉粥样硬化和血栓形成,主动脉冠状动脉大隐静脉旁路移植血管常出现阻塞性改变。我们研究了积极降低低密度脂蛋白(LDL)胆固醇水平或小剂量抗凝是否会延缓移植血管中动脉粥样硬化的进展。

方法

我们研究了1351例在基线前1至11年接受过搭桥手术、LDL胆固醇水平在130至175mg/dL之间且血管造影显示至少有一条移植静脉通畅的患者。我们采用二乘二析因设计,将患者分为积极或适度治疗以降低LDL胆固醇水平(使用洛伐他汀,必要时加用考来烯胺)以及接受华法林或安慰剂治疗。在基线后平均4.3年重复进行血管造影。主要血管造影结果是每位患者移植血管中管腔直径减小0.6mm或更多的平均百分比。

结果

在研究期间每年测量,积极治疗患者的平均LDL胆固醇水平为93至97mg/dL;适度治疗患者的范围为132至136mg/dL(P<0.001)。华法林组的平均国际标准化比值为1.4,安慰剂组为1.1(P<0.001)。积极治疗降低LDL胆固醇水平的患者中,移植血管发生动脉粥样硬化进展的平均百分比为27%,接受适度治疗的患者为39%(P<0.001)。华法林组和安慰剂组的血管造影结果无显著差异。积极降低LDL胆固醇水平的组在四年内的血运重建率比接受适度治疗的组低29%(6.5%对9.2%,P = 0.03)。

结论

将LDL胆固醇水平积极降低至100mg/dL以下可减少移植血管中动脉粥样硬化的进展。小剂量华法林并不能减少动脉粥样硬化的进展。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验